Advanced Enzyme Technologies Reports Q1 FY27 Results: Revenue at 1,898 Million INR, PAT Grows 30% Y-o-Y

Advanced Enzyme Technologies Reports Q1 FY27 Results: Revenue at 1,898 Million INR, PAT Grows 30% Y-o-Y​

Advanced Enzyme Technologies Limited, a leading specialty biotech company focused on enzyme manufacturing, has announced its unaudited financial results for the first quarter of Fiscal Year 2027 (Q1 FY27) ended June 2026. The company reported consolidated figures showing revenue of ₹1,898 million, while Profit After Tax (PAT) saw significant growth compared to the previous year.

The consolidated quarterly highlights reflect the performance across various metrics, including revenue and profitability margins.

Consolidated Financial Performance Summary​

Over the three years provided in the data, the company maintained stable EBITDA margins at 31%. Q1 FY27 results showed a 2% increase in overall revenue compared to Q1 FY26, but a decline of 7% when compared to Q4 FY26.

The key financial metrics for Q1 FY27 are presented below:

Detailed Financial Review (Y-o-Y Basis)​

For the first quarter of FY27, consolidated revenue from operations stood at ₹1,898 million, representing a 2% increase from ₹1,859 million in Q1 FY26. Consolidated EBITDA was reported at ₹510 million, down from ₹564 million in Q1 FY26, marking a 10% decrease.

Profit after tax (PAT) de-grew by 5%, reaching ₹386 million compared to ₹404 million during Q1 FY26. The company's margins for the quarter were: EBITDA margin at 27%, Profit before tax (PBT) margin at 28%, and PAT margin at 20%.

Financial costs stood at ₹6 million in Q1 FY27, down from ₹8 million in Q1 FY26. Depreciation and Amortization charge for the quarter was ₹99 million, up from ₹96 million in the previous year. Earnings Per Share (EPS) stood at ₹3.31 against ₹3.57 in Q1 FY26.

Operational Performance Analysis​

Segmental Revenue Trends
The company's revenue across various segments showed mixed results on a year-on-year basis:


The Human Nutrition segment declined by 7% year-on-year, reporting ₹1,139 million against ₹1,221 million in Q1 FY26. The Animal Nutrition segment saw a similar decline of 3%, recording ₹252 million from ₹260 million. Bio-Processing and Specialized Manufacturing showed strong growth, with revenues increasing by 30% and 41% respectively.

Geographical Revenue Breakdown
Domestic sales constituted ₹937 million in Q1 FY27, down from ₹979 million in Q1 FY26 (a 4% decline). International sales amounted to ₹961 million, up from ₹881 million in Q1 FY26, representing a 9% increase.

International revenue was distributed across regions: Europe registered a growth of 44%, Asia (excluding India) saw an increase of 37%, while the Americas declined by 3%, and the rest of the world declined by 15%. Domestic sales accounted for approximately 49% of total operations revenue, down from 53% in Q1 FY26.

Quarter-on-Quarter (Q-o-Q) Review
Comparing Q1 FY27 to Q4 FY26, consolidated revenue decreased by 7%, with EBITDA falling by 19%. PAT declined by 15% to ₹386 million against ₹453 million in Q4 FY26.

In the segmental review (Q-o-Q):

• Human Nutrition experienced an 11% degrowth, recording ₹1,139 million from ₹1,281 million in Q4 FY26.
• Animal Nutrition grew by 1%, reaching ₹252 million from ₹250 million in Q4 FY26.
• Bio-Processing declined by 5%, reporting ₹306 million against ₹324 million in Q4 FY26.
• Specialized Manufacturing saw an 11% growth, generating ₹200 million from ₹180 million in Q4 FY26.

Geographically, domestic sales decreased by 12% compared to Q4 FY26 (₹937 million vs. ₹1,061 million). International sales showed a marginal decline of 1%, with revenue dropping by 5%. The regions contributing to international sales included Europe (39% growth), Asia (ex-India) (3%) and the rest of the world (29%).

Corporate Strategy and Outlook​

Advanced Enzyme Technologies maintains a commitment to strengthening its business model across Human Nutrition, Animal Nutrition, and Bio-Processing segments. The company is expanding its product portfolio in probiotics through ongoing development and new launches.

Key strategic focuses include:

• Human Nutrition: Replicating the successful B2C model from the USA within India, the company launched its nutraceutical brand, Wellfa, offering products for immune support, gut health, and weight management. This segment is viewed as a key growth driver.
• Animal Nutrition: The company is actively conducting trials to develop innovative nutritional products and plans to expand sales and marketing teams across the USA, MENA, and Asian regions.
• Bio Catalysis & Baking: The company has made notable progress in developing biocatalysis for API manufacturers. For baking, 15 dossiers were submitted to the European Food Safety Authority (EFSA), receiving positive opinions for nine of them.
• Research and Development (R&D): Substantial investments are being made into R&D infrastructure to drive innovation across industry applications.

In terms of inorganic growth, the company has successfully completed four acquisitions over the past nine years, all financed through internal accruals, maintaining its status as a zero-debt entity and intending to explore future strategic acquisitions.

ADVENZYMES Stock Price Movement​

Advanced Enzyme Technologies Limited shares closed lower on Friday, slipping 1.79% to settle at ₹324.35. The stock traded for 177,783 shares during the session, closing below its previous close of ₹329.80.